In both human beings and dogs, local tumor recurrence following surgical removal of solid tumors is a major cause of treatment failure. An important technical limitation is that there is currently no widely available technique for rapid evaluation of the completeness of tumor removal during surgery. To address this need, a handheld imaging device has been developed that can be used in conjunction with injectable fluorescent imaging agents that accumulate in cancerous tissue and are administered to the patient prior to surgery. The imaging device can be used to scan the tumor bed for residual tissue to identify cancer that has not been removed. Removing this tissue has potential to reduce local recurrence rates. The objective of this project is to test the accuracy of the system in distinguishing normal tissue from cancerous tissue in dogs undergoing resection of carcinomas, a common category of cancer in dogs. We hypothesize that the system will have a high level of accuracy in this application.
Any dog with naturally occurring liver carcinoma. Informed client consent will be obtained prior to entering dogs in the study.
You will receive a $500.00 reduction in your total bill as an incentive to participate in this study, and you will not be charged for your initial office visit. Your pet’s participation will allow us to gain information that will help in the treatment of other dogs, cats, and humans undergoing surgical resection of malignant tumors.
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: firstname.lastname@example.org
Is Your Pet Eligible?
If you believe that your pet may be eligible for this study, please complete our prescreening questionnaire for owners.
If you believe you have a patient who is eligible for this clinical trial study or you would like additional information from the Clinical Trials Office at the Cummings Veterinary Medical Center, complete a referring physician questionnaire.